Humanized mouse models in MDS
Por:
Munteanu, R, Gulei, D, Moldovan, CS, Azzoni, E, Belver, L, Feder, R, Pirv, S, Buzoianu, AD, Einsele, H, Mittelman, M, Ghiaur, G, Hasserjian, R and Tomuleasa, C
Publicada:
17 jul 2025
Ahead of Print:
17 jul 2025
Resumen:
Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem cell disorders defined by ineffective hematopoiesis, multilineage dysplasia, and risk of progression to acute myeloid leukemia. Improvements have been made to identify recurrent genetic mutations and their functional roles, but translating this into preclinical models is still difficult. Traditional murine systems lack the human-specific cytokine support and microenvironmental support that is necessary to reproduce MDS pathophysiology. Humanized mouse models, particularly those incorporating human cytokines (e.g., MISTRG, NSG-SGM3, NOG-EXL), immunodeficient backgrounds, and co-transplantation strategies, have improved the engraftment and differentiation of human hematopoietic stem and progenitor cells. These models allow the study of clonal evolution, mutation-specific disease dynamics, and response to therapies in vivo. However, difficulties persist, such as limited long-term engraftment, incomplete immune reconstruction, and limited possibilities of modeling early-stage or low-risk MDS. This review presents an overview of current humanized and genetically engineered mouse models suitable for studying MDS, evaluating their capacity to replicate disease complexity, preserve clonal architecture, and support translational research. We highlight the need to develop new approaches to improve the actual methodologies and propose future directions for standardization and improved clinical relevance.
Filiaciones:
Munteanu, R:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Gulei, D:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Moldovan, CS:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Nanosci, Cluj Napoca, Romania
Azzoni, E:
Univ Milano Bicocca, Sch Med & Surg, Monza, Italy
Fdn IRCCS San Gerardo Tintori, Monza, Italy
:
Josep Carreras Leukaemia Res Inst, Badalona, Barcelona, Spain
Catalan Inst Oncol, Canc Therapeut Resistance Program ProCURE, Badalona, Barcelona, Spain
Feder, R:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Pirv, S:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Buzoianu, AD:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Einsele, H:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
Mittelman, M:
Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel
Ghiaur, G:
Johns Hopkins Univ, Sidney Kimmel Canc Ctr Johns Hopkins, Dept Leukemia, Sch Med, Baltimore, MD USA
Hasserjian, R:
Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA
Tomuleasa, C:
Iuliu Hatieganu Univ Med & Pharm, Medfuture Inst Biomed Res, Dept Personalized Med & Rare Dis, Cluj Napoca, Romania
Ion Chiricuta Oncol Inst, Dept Hematol, Cluj Napoca, Romania
Iuliu Hatieganu Univ Med & Pharm, Dept Hematol, Cluj Napoca, Romania
Green Submitted, gold
|